YS Biopharma (YS) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free YS Stock Alerts $0.95 -0.08 (-7.77%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comYS Biopharma Co., Ltd. (NASDAQ:YS) Sees Large Decrease in Short InterestMay 7, 2024 | prnewswire.comYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerMay 7, 2024 | finance.yahoo.comWith 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's futureApril 29, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | prnewswire.comYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 25, 2024 | marketbeat.comFY2024 EPS Estimates for YS Biopharma Co., Ltd. (NASDAQ:YS) Lowered by AnalystYS Biopharma Co., Ltd. (NASDAQ:YS - Free Report) - Equities researchers at Diamond Equity decreased their FY2024 earnings per share estimates for shares of YS Biopharma in a research note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now anticipates that the companyApril 22, 2024 | finance.yahoo.comYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call TranscriptApril 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | markets.businessinsider.comYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024April 19, 2024 | prnewswire.comYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 18, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineApril 18, 2024 | prnewswire.comYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineApril 16, 2024 | finance.yahoo.comYS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024April 9, 2024 | msn.comChinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved CompetitorApril 9, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 9, 2024 | finance.yahoo.comYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 9, 2024 | prnewswire.comYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies VaccineApril 3, 2024 | finance.yahoo.comYS Biopharma Announces Full Repayment of US$40,000,000 Loan FacilityMarch 28, 2024 | msn.comTechnology and demographics affect hiring and pay strategiesMarch 5, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesMarch 5, 2024 | finance.yahoo.comYS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese SubsidiariesFebruary 22, 2024 | finance.yahoo.comYS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024February 17, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 17, 2024 | finance.yahoo.comYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 16, 2024 | prnewswire.comYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the MeetingFebruary 16, 2024 | finance.yahoo.comShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.February 16, 2024 | prnewswire.comShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.February 14, 2024 | finance.yahoo.comYS Biopharma Announces Appointment of New DirectorsFebruary 14, 2024 | finance.yahoo.comYS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate GovernanceFebruary 14, 2024 | prnewswire.comYS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate GovernanceFebruary 14, 2024 | prnewswire.comYS Biopharma Announces Appointment of New DirectorsFebruary 12, 2024 | finance.yahoo.comYS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.February 9, 2024 | finance.yahoo.comYS Biopharma Announces US$40 Million Private Placement FinancingFebruary 8, 2024 | finance.yahoo.comShareholders of YS Biopharma Announce an Extraordinary General MeetingJanuary 24, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024January 22, 2024 | finance.yahoo.comYS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024January 8, 2024 | finance.yahoo.comYS Biopharma Announces Changes to its Board CommitteesDecember 20, 2023 | marketwatch.comYS Biopharma Says Fake Press Release Called for Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comYS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comYS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023December 18, 2023 | msn.comLantheus and Point Biopharma shares drop on prostate cancer treatment dataNovember 15, 2023 | finance.yahoo.comWhen Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?November 14, 2023 | msn.comNoble Capital Markets Initiates Coverage of YS Biopharma (YS) with Outperform RecommendationNovember 14, 2023 | forbes.comBiopharma Has No Choice But To Comply With Price ControlsOctober 31, 2023 | finance.yahoo.comYS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies VaccineOctober 26, 2023 | msn.comYS Biopharma receives Nasdaq notice regarding minimum bid price requirementOctober 26, 2023 | finance.yahoo.comYS Biopharma Announces Receipt of Nasdaq NoticeOctober 10, 2023 | finance.yahoo.comUPDATE - Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS)September 28, 2023 | msn.comYS Biopharma enrols first subject in PIKA Rabies Vaccine study Get YS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter. Email Address Americans Now Need $1.46M to Retire… (Ad)Americans now say they need $1.46M in order to “retire comfortably.” For many, retiring in your 60s may be out of the picture altogether… But luckily for you – a limited window in today’s crypto market could help you retire quickly in wealth AND comfort! Click here to access the free Crypto Retirement Blueprint now. YS Media Mentions By Week YS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YS News Sentiment▼1.580.54▲Average Medical News Sentiment YS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YS Articles This Week▼31▲YS Articles Average Week Get YS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ProPhase Labs News Today Eton Pharmaceuticals News Today Oncolytics Biotech News Today Vaccitech News Today Aclaris Therapeutics News Today Milestone Pharmaceuticals News Today Chimerix News Today LifeVantage News Today BeyondSpring News Today Spero Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YS) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
